BBOT
NASDAQ · Biotechnology
Bridgebio Oncology Therapeut
$2.17
-0.13 (-5.65%)
Open$2.30
Previous Close$2.30
Day High$2.30
Day Low$2.07
52W High$14.87
52W Low$2.22
Volume—
Avg Volume644.5K
Market Cap173.98M
P/E Ratio—
EPS$-3.04
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+1,886.2% upside
Current
$2.17
$2.17
Target
$43.10
$43.10
$22.76
$43.10 avg
$48.38
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 230.06M | 225.69M | 230.96M |
| Net Income | 46.84M | 61.14M | 59.73M |
| Profit Margin | 20.4% | 27.1% | 25.9% |
| EBITDA | 108.29M | 111.55M | 110.87M |
| Free Cash Flow | 56.78M | 36.61M | 55.99M |
| Rev Growth | -2.3% | +22.3% | +7.3% |
| Debt/Equity | 0.31 | 0.27 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |